Teitur Trophics
Aarhus, DK · Founded 2020 · 5 known investors
Teitur Trophics is a biotech company developing first-in-class cyclic peptides that target lysosomal, mitochondrial and pro-survival signaling pathways to preserve neuronal function. Its lead candidate, TT-P34, is a subcutaneous peptide in Phase I clinical development as a disease-modifying therapy for neurodegenerative diseases including Parkinson's, Huntington's disease and frontotemporal dementia.
BiotechDeep TechHealthtech
Founders & leadership
Teitur Trophics was founded in 2020 by Simon Mølgaard, Anders Dalby, Mathias Ollendorff, and Simon Glerup.
SM
Simon MølgaardCo-founder & CEO
AD
Anders DalbyCo-founder
MO
Mathias OllendorffCo-founder
SG
Simon GlerupCo-founder
Investors · 5
In the news
Frequently asked questions
- What does Teitur Trophics do?
- Teitur Trophics is a biotech company developing first-in-class cyclic peptides that target lysosomal, mitochondrial and pro-survival signaling pathways to preserve neuronal function. Its lead candidate, TT-P34, is a subcutaneous peptide in Phase I clinical development as a disease-modifying therapy for neurodegenerative diseases including Parkinson's, Huntington's disease and frontotemporal dementia.
- Who founded Teitur Trophics?
- Teitur Trophics was founded by Simon Mølgaard, Anders Dalby, Mathias Ollendorff, Simon Glerup in 2020.
- Who are Teitur Trophics's investors?
- Teitur Trophics's investors include Industrifonden, P53 Invest, Innovestor, Sound Bioventures, Sunstone Capital.
- Where is Teitur Trophics headquartered?
- Teitur Trophics is headquartered in Aarhus, DK.